
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VOY-101
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Details : VOY-101 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Degeneration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 17, 2023
Lead Product(s) : VOY-101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $78.0 million
Deal Type : Series B Financing
Perceive Biotherapeutics Attracts $78M Series B Financing to Advance Diversified Pipeline
Details : The net proceeds from the funding will be used to fuel Perceive Biotherapeutics progress as it drives lead AMD program into the clinic and continues development progress across extensive ophthalmology pipeline.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : Johnson & Johnson
Deal Size : $78.0 million
Deal Type : Series B Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : VOY-101
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Details : VOY-101 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Macular Degeneration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : VOY-101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
